We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
Anatara Lifesciences (ASX: ANR) has reported that recruitment for Stage 2 of its pivotal GaRP (Gastr...
Read ArticleRecruitment is advancing for Stage 2 of Anatara Lifesciences’ (ASX: ANR) pivotal gastrointestinal re...
Read ArticleAnatara Lifesciences (ASX: ANR) has initiated Stage 2 of a Phase II gastrointestinal re-programming...
Read ArticleSteve Lydeamore’s advice to biotech peers seeking to do business with the US military is to be armed...
Read ArticleAnatara Lifesciences (ASX:ANR) has announced that it has received firm commitments for a pla...
Read ArticleIrritable bowel syndrome (IBS) is well-named, many sufferers are unaware of why they are feeling so...
Read ArticleAnatara Lifesciences (ASX: ANR) is inviting members of the public to register their interest in Stag...
Read ArticleThe ASX has ended the week lower, down 0.55pc on Friday Healthcare Sector remains defiant Small ca...
Read ArticleAVITA jumps after providing bullish guidance Anatara up after holding AGM this morning Imugene dose...
Read ArticleGood morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and...
Read ArticleAnatara Lifesciences (ASX:ANR) has announced further data from the interim analysis of stage...
Read ArticleAnatara to progress in Phase 1/2 clinical trial of bowel syndrome Noxopharm to present data at conf...
Read ArticleBenchmark index settles almost -0.6% lower on Tuesday All sectors bar Healthcare and Financials in...
Read ArticleAnatara Lifesciences (ASX:ANR) has provided an update on the Gastrointestinal ReProgramming...
Read ArticleThe ASX set to fall on Tuesday, tracking movements on Wall Street Binance CEO charged by the US SEC...
Read ArticleAnatara Life’s (ANR) 200-patient Gastrointestinal ReProgramming (GaRP) trial gains momentum, with en...
Read ArticleVolpara’s share price rose 10% this morning after the US FDA finalised a new federal regulation on...
Read ArticleAnatara Lifesciences (ANR) enters into a trading halt while it plans a capital raiseThe company has...
Read ArticleIt’s Wednesday. Hump day. And boy-oh-boy are some of us feeling well and truly humped as it draws to...
Read ArticleAnatara Lifesciences (ANR) receives ethics approval to expand eligibility criteria for its Irritabl...
Read ArticleMicroba will progress to preclinical trial in 2022 Anatara’s CEO resigns Newly listed Microba Life...
Read ArticleThe ASX 200 Health Index (XHJ) has dropped by almost 5% at the time of writing, compared to the broa...
Read ArticleMicroba Life Sciences will work with Anatara Life Sciences (ASX:ANR) to complete microbiome...
Read ArticleSummary ASX-listed animal health business Apiam disclosed the acquisition of Golden Plains Grou...
Read ArticleThe Anatara Lifesciences Ltd (ASX: ANR) share price is one of the best performers on the ASX today....
Read ArticleSource: Krisana Antharith, Shutterstock While the benchmark index, ASX200 was marginally down, two...
Read ArticleStockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) per...
Read ArticleA quick wrap of the ASX’s key winners and losers on Friday, August 21. Data is taken after the marke...
Read ArticleA quick wrap of the ASX’s key winners and losers on Tuesday, August 18. Data is taken after the mark...
Read ArticleNearly two years of pain for Factor Therapeutics (ASX:FTT) shareholders could be over soon with the...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleSmall caps can make investors very wealthy, but can they do the same for our nation? Australia’s mai...
Read ArticleGastrointestinal diseases are among the most inconvenient types of illnesses to have, and not just b...
Read ArticleGot 90 seconds? Then listen to Anatara Lifesciences CEO Steven Lydeamore tell us about his company’...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 134-odd small ca...
Read ArticleThe European Commission has granted Orphan drug status for Alterity Therapeutics’ (ASX:ATH) lead mol...
Read ArticleWho needs human companionship when we have pets? They’re loyal, always happy to see you and won’t di...
Read ArticleAt first glance, the health and life sciences sector on the ASX appears vibrant. There are several s...
Read ArticleStockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and pickin...
Read ArticleThe 10th Annual Australian Microcap Investment Conference will be held on Tuesday 22 October 2019 ov...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleQueenstown is known as the adventure capital of the world. It attracts over three million people per...
Read ArticleAnatara Lifesciences: Anatara can still partner Detach By Pitt Street Research On 14 June 2019, Anat...
Read ArticlePenny stocks are those common stocks whose share price is less than $1. In other words, Penny stocks...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
